Moody Aldrich Partners’s Revolution Medicines RVMD Stock Holding History

Moody Aldrich Partners’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$366K	Buy	+1,952	New	+$285K	0.07%	138

Other funds holding RVMD

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

WPC

Wedmont Private Capital West Chester, Pennsylvania $3.65B AUM 26.64% 1-Year Est. Return

SCA

Sandy Cove Advisors Hingham, Massachusetts $400M AUM 27.68% 1-Year Est. Return

SWM

Spire Wealth Management Mclean, Virginia $3.31B AUM 38.78% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

QCM

QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return

CPM

Connective Portfolio Management New York $60.1M AUM 88.93% 1-Year Est. Return

EOJOAM

E. Ohman J:or Asset Management Stockholm, Sweden $4.3B AUM 29.55% 1-Year Est. Return

Moody Aldrich Partners's RVMD Position: Q2 2026 in Review

Moody Aldrich Partners opened a new position in Revolution Medicines (RVMD) in Q2 2026: 1,952 shares worth $366K. The stake represents 0.07% of the portfolio and ranks #138 among its holdings.

66 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

Moody Aldrich Partners held 1,952 shares of Revolution Medicines worth $366K as of Q2 2026.
Revolution Medicines was a new Moody Aldrich Partners position in Q2 2026.
Revolution Medicines made up 0.07% of Moody Aldrich Partners's portfolio in Q2 2026, its #138 holding.
66 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Moody Aldrich Partners's 13F filing for Q2 2026, filed 15 Jul 2026.